Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 12/20 | 0.49 |
| ▸ | AKT2 | P31751 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13407633 | 0.81 | AKT2 (0.49) | HDAC1AKT2KDM4EALDH1A1RAB9A | |
| SCHEMBL8253610 | 0.78 | AKT2 (0.48) | HDAC1AKT2KDM4EALDH1A1RAB9A | |
| SCHEMBL13407632 | 0.78 | AKT2 (0.48) | HDAC1AKT2KDM4EALDH1A1RAB9A | |
| SCHEMBL3550040 | 0.78 | HDAC1 (0.83) | HDAC1 | |
| SCHEMBL3550042 | 0.78 | HDAC1 (0.83) | HDAC1 | |
| SCHEMBL28393023 | 0.76 | AKT2 (0.46) | HDAC1AKT2RAB9A | |
| SCHEMBL28624230 | 0.74 | HDAC1 (0.60) | HDAC1KDM4EALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL28630916 | 0.73 | HDAC1 (0.59) | HDAC1AKT2KDM4EALDH1A1RAB9A | |
| SCHEMBL28630210 | 0.71 | HDAC1 (0.57) | HDAC1AKT2KDM4EALDH1A1RAB9A | |
| SCHEMBL17113969 | 0.71 | AKT2 (0.54) | AKT2KDM4EALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266882-B2 | Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications | MEI PHARMA, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266882-B2 | Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications | MEI PHARMA, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150038703-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HELSINN HEALTHCARE SA (CH) | 2015-02-05 | — | — | US | disclosed |
| US-20150038703-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HELSINN HEALTHCARE SA (CH) | 2015-02-05 | — | — | US | disclosed |
| US-8901149-B2 | Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications | MEI PHARMA, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8648092-B2 | Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications | MEI Pharma (US) | 2014-02-11 | — | — | US | disclosed |
| US-8648092-B2 | Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications | MEI Pharma (US) | 2014-02-11 | — | — | US | disclosed |
| US-20100105721-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2010-04-29 | — | — | US | disclosed |
| US-20100105721-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2010-04-29 | — | — | US | disclosed |
| US-7666880-B2 | Hydroxamate compounds which are inhibitors of histone deacetylase; may be useful as medicaments for treatment of proliferative disorders as well as other diseases involving, relating to, or associated with enzymes having histone deacetylase activities such as neurodegenerative, cardiovascular disorders | S*BIO PTE LTD. (SG) | 2010-02-23 | — | — | US | disclosed |
| US-7666880-B2 | Hydroxamate compounds which are inhibitors of histone deacetylase; may be useful as medicaments for treatment of proliferative disorders as well as other diseases involving, relating to, or associated with enzymes having histone deacetylase activities such as neurodegenerative, cardiovascular disorders | S*BIO PTE LTD. (SG) | 2010-02-23 | — | — | US | disclosed |
| US-20080085896-A1 | Hydroxamate compounds which are inhibitors of histone deacetylase; may be useful as medicaments for treatment of proliferative disorders as well as other diseases involving, relating to, or associated with enzymes having histone deacetylase activities such as neurodegenerative, cardiovascular disorders | S*BIO PTE LTD. (SG) | 2008-04-10 | — | — | US | disclosed |
| US-20080085896-A1 | Hydroxamate compounds which are inhibitors of histone deacetylase; may be useful as medicaments for treatment of proliferative disorders as well as other diseases involving, relating to, or associated with enzymes having histone deacetylase activities such as neurodegenerative, cardiovascular disorders | S*BIO PTE LTD. (SG) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085896-A1 | Hydroxamate compounds which are inhibitors of histone deacetylase; may be useful as medicaments for treatment of proliferative disorders as well as other diseases involving, relating to, or associated with enzymes having histone deacetylase activities such as neurodegenerative, cardiovascular disorders | HDAC1, HDAC5, HDAC11 | HDAC1 1/4885AKT2 3168/4885KDM4E 672/4885 |
| US-20100105721-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HDAC1, HDAC2, HDAC5 | HDAC1 1/4885AKT2 3118/4885KDM4E 251/4885 |
| US-20150038703-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HDAC1, HDAC2, HDAC5 | HDAC1 1/4885AKT2 3118/4885KDM4E 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.